Teva Pharmaceutical recalls 38,858 bottles of drugs made by Emcure Pharmaceuticals in US market
The company is also recalling 7,694 bottles of anti- inflammatory drug indomethacin 25 mg, produced by Emcure Pharma, for non-adherence to CGMP. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2014 Category: Pharmaceuticals Source Type: news
Tivorbex (indomethacin) for the Treatment of Acute Pain
Tivorbex (indomethacin) is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of mild to moderate acute pain in adults. (Source: Drug Development Technology)
Source: Drug Development Technology - March 28, 2014 Category: Pharmaceuticals Source Type: news
CNS effects of indomethacin: should patients be cautioned about decreased mental alertness and motor coordination? - Hegeman J, van den Bemt B, Weerdesteyn V, Nienhuis B, van Limbeek J, Duysens J.
AIMS: In many European countries as well as in the USA, the leaflet, or even the packaging of indomethacin, contains a specific warning to refrain from activities requiring mental alertness and motor coordination, such as driving a car. In this placebo-con... (Source: SafetyLit: All (Unduplicated))
Source: SafetyLit: All (Unduplicated) - March 5, 2014 Category: Global & Universal Tags: Alcohol and Other Drugs Source Type: news
Tivorbex (Indomethacin Capsules) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 5, 2014 Category: Drugs & Pharmacology Source Type: news
Iroko's lower dose pain drug Tivorbex obtains FDA approval
US-based Iroko Pharmaceuticals has received approval from the US Food and Drug Administration (FDA) to use Tivorbex (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20mg and 40mg doses to treat mild to moderate acute pain in… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 26, 2014 Category: Pharmaceuticals Source Type: news
FDA Approves Another Lower-Dose NSAIDFDA Approves Another Lower-Dose NSAID
The new product, indomethacin 20 mg and 40 mg, is the company's second lower-dose NSAID to get FDA approval in about 4 months FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - February 25, 2014 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Pro ArthMax by Human Science Foundation: Recall - Undeclared Drug Ingredients
Undeclared Chlorzoxazone, Nefopam, Diclofenac, Ibuprofen, Naproxen, and Indomethacin. Pro ArthMax has a reasonable probability of resulting in fatal adverse events. (Source: FDA MedWatch)
Source: FDA MedWatch - January 14, 2014 Category: American Health Source Type: news
indomethacin, Indocin, Indocin-SR (Discontinued Brand in U.S.)
Title: indomethacin, Indocin, Indocin-SR (Discontinued Brand in U.S.)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/5/2013 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - December 5, 2013 Category: Drugs & Pharmacology Source Type: news
indomethacin, Indocin, Indocin-SR (Discontinued Brand in U.S.)
Title: indomethacin, Indocin, Indocin-SR (Discontinued Brand in U.S.)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 12/5/2013 12:00:00 AM (Source: MedicineNet Migraine General)
Source: MedicineNet Migraine General - December 5, 2013 Category: Neurology Source Type: news
Rectal Indomethacin and Pancreatic Stents in High-Risk ERCPRectal Indomethacin and Pancreatic Stents in High-Risk ERCP
Do patients undergoing high-risk ERCP benefit from rectal indomethacin, or are prophylactic pancreatic stents still considered necessary? The American Journal of Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 23, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Submicron NSAIDs Demonstrate Efficacy At Lower Doses In Studies In Patients With Acute And Chronic Pain
Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, is presenting positive Phase 3 data from its investigational submicron non-steroidal anti-inflammatory drug (NSAID) pipeline at two medical meetings. These presentations summarize the results of studies of lower dose submicron indomethacin in patients with post surgical pain, and lower dose submicron diclofenac in patients with osteoarthritis pain... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 15, 2013 Category: Consumer Health News Tags: Pain / Anesthetics Source Type: news
Iroko reports positive results from Phase III submicron indomethacin and diclofenac studies
Iroko Pharmaceuticals has reported positive results from its Phase III studies of lower dose submicron indomethacin in patients with post-surgical pain, and lower dose submicron diclofenac in patients with osteoarthritis pain. (Source: Drug Development Technology)
Source: Drug Development Technology - April 11, 2013 Category: Pharmaceuticals Source Type: news
